Alvotech (ALVOW) Change in Accured Expenses (2021 - 2025)
Alvotech (ALVOW) reported Change in Accured Expenses of -$26.8 million for Q3 2025, down 111.99% on a YoY basis from $224.0 million in Q3 2024, and down 230.73% quarter-over-quarter from $20.5 million in Q2 2025.
Alvotech (ALVOW) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Alvotech has reported Change in Accured Expenses for 5 years, with the latest figure at -$26.8 million in Q3 2025.
- For the quarter ending Q3 2025, Change in Accured Expenses fell 111.99% year-over-year to -$26.8 million; the trailing twelve-month figure through Sep 2025 stood at -$33.0 million (down 38.14% YoY), and the FY2023 full-year result was -$5.2 million, up 75.77% from the prior year.
- Change in Accured Expenses for Q3 2025 stood at -$26.8 million, down from $20.5 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $20.5 million in Q2 2025, with the low at -$26.8 million in Q3 2025.
- Historically, Change in Accured Expenses has averaged -$5.1 million across 5 years, with a median of -$5.2 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 580.22% — and 2025, when it soared 1796.31%.
- Alvotech's Change in Accured Expenses stood at $4.5 million in 2021, then plunged by 580.22% to -$21.4 million in 2022, then jumped by 75.77% to -$5.2 million in 2023, then slumped by 175.94% to -$14.3 million in 2024, then slumped by 87.76% to -$26.8 million in 2025.
- The last three Change in Accured Expenses figures came in at -$26.8 million (Q3 2025), $20.5 million (Q2 2025), and -$12.4 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 23.00 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 10.02 Mn |
| 10 | Alvotech | - | - | -22.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -26.85 Mn |
| Sep 30, 2025 | -26.85 Mn |
| Jun 30, 2025 | 20.54 Mn |
| Jun 30, 2025 | 20.54 Mn |
| Mar 31, 2025 | -12.41 Mn |
| Mar 31, 2025 | -12.41 Mn |
| Dec 31, 2024 | -14.30 Mn |
| Dec 31, 2024 | -14.30 Mn |
| Sep 30, 2024 | -12.67 Mn |
| Sep 30, 2024 | -12.67 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | -7.14 Mn |
| Mar 31, 2024 | -7.14 Mn |
| Dec 31, 2023 | -5.18 Mn |
| Dec 31, 2023 | -5.18 Mn |
| Jun 30, 2023 | 8.87 Mn |
| Jun 30, 2023 | 8.87 Mn |
| Mar 31, 2023 | -4.48 Mn |
| Mar 31, 2023 | -4.48 Mn |